济川药业：蒲地蓝消炎口服液的OTC包装已陆续在全国各大零售药店上架

Core Viewpoint - Jichuan Pharmaceutical is focusing on enhancing its brand and offline coverage for its daily chemical products, with significant progress in terminal store coverage and product approvals [1] Group 1: Product Development and Approval - Pudilan Oral Liquid has been approved in 2024 as a dual-category drug, allowing it to be classified as both a prescription and an over-the-counter medication. The OTC packaging is now available in major retail pharmacies nationwide [1] - The new chemical drug, Marcilosavir Tablets, developed in collaboration with Nanjing Zhengxiang Pharmaceutical Co., Ltd., received approval in July 2025. This product is designed to alleviate flu symptoms with a single oral dose, although it will require a market development period before launch [1] Group 2: Market Strategy - The company emphasizes brand building and offline coverage for its daily chemical products by precisely targeting core markets, deepening existing customer engagement, and expanding new customer acquisition through a replicable benchmark model [1] - The offline terminal coverage has reached thousands of stores, indicating a strong commitment to increasing market presence [1]